hsa-miR-9 controls the mobility behavior of glioblastoma cells  via  regulation of MAPK14 signaling elements

Rotem Ben-Hamo; Alona Zilberberg; Helit Cohen; Sol Efroni

doi:10.18632/oncotarget.6687

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements

Rotem Ben-Hamo, Alona Zilberberg, Helit Cohen and Sol Efroni _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:23170-23181. https://doi.org/10.18632/oncotarget.6687

Metrics: PDF 2291 views | HTML 2706 views | ?

Abstract

Rotem Ben-Hamo1, Alona Zilberberg1, Helit Cohen1 and Sol Efroni1

1 The Mina and Everard Goodman Faculty of Life Science, Bar Ilan University, Ramat-Gan, Israel

Correspondence to:

Sol Efroni, email:

Keywords: MAPKAP signaling, cytoskeleton, pathways, glioblastoma, metastasis, hsa-miR9

Received: July 23, 2015 Accepted: December 05, 2015 Published: December 21, 2015

Abstract

Background: Glioblastoma Multiforme (GBM) is the most common and lethal primary tumor of the brain. GBM is associated with one of the worst 5-year survival rates among all human cancers, despite much effort in different modes of treatment.

Results: Here, we demonstrate specific GBM cancer phenotypes that are governed by modifications to the MAPAKAP network. We then demonstrate a novel regulation mode by which a set of five key factors of the MAPKAP pathway are regulated by the same microRNA, hsa-miR-9.

We demonstrate that hsa-miR-9 overexpression leads to MAPKAP signaling inhibition, partially by interfering with the MAPK14/MAPKAP3 complex. Further, hsa-miR-9 overexpression initiates re-arrangement of actin filaments, which leads us to hypothesize a mechanism for the observed phenotypic shift.

Conclusion: The work presented here exposes novel microRNA features and situates hsa-miR-9 as a therapeutic target, which governs metastasis and thus determines prognosis in GBM through MAPKAP signaling.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6687

Publication Alerts

Research Papers:

hsa-miR-9 controls the mobility behavior of glioblastoma cells via regulation of MAPK14 signaling elements

Abstract